Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
5.70
-0.03 (-0.52%)
At close: Apr 24, 2026, 4:00 PM EDT
5.76
+0.06 (1.05%)
After-hours: Apr 24, 2026, 4:33 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 16 employees as of December 31, 2025. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$2,173,125
Market Cap
49.08M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 15 | 0 |
| Dec 31, 2023 | 12 | 1 | 9.09% | 12 | 0 |
| Dec 31, 2022 | 11 | 3 | 37.50% | 11 | 0 |
| Dec 31, 2021 | 8 | 0 | - | 6 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Plus Therapeutics | 28 |
| PDS Biotechnology | 24 |
| MiNK Therapeutics | 23 |
| Nutriband | 13 |
| Rein Therapeutics | 10 |
| Dogwood Therapeutics | 8 |
ATOS News
- 4 weeks ago - Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 5 weeks ago - Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PRNewsWire
- 6 weeks ago - Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - PRNewsWire
- 2 months ago - Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - PRNewsWire
- 2 months ago - Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - PRNewsWire
- 3 months ago - Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - PRNewsWire
- 3 months ago - Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - PRNewsWire
- 3 months ago - Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer - PRNewsWire